Novo may have muscle advantage over Lilly in weight-loss race: preprint
BioSpace
More patients on Eli Lilly's tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk's semaglutide, according to a study that has yet to be peer reviewed.
pharminent
April 17, 2026 (Last updated: April 17, 2026)
BioSpace
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.
